Pharming (PHAR) Non Operating Investment Income (2019 - 2024)
Pharming (PHAR) posted Non Operating Investment Income of -$0.2 for Q4 2024, up 100.0% on a QoQ basis from -$21000.0 in Q3 2024, and down 100.0% year-over-year from $930000.0 in Q1 2024.
Pharming (PHAR) Non Operating Investment Income (2019 - 2024) Analysis & Trends
Pharming's Non Operating Investment Income history runs 6 years deep, the most recent figure standing at -$0.2 for Q4 2024.
- Quarterly Non Operating Investment Income fell 100.0% year-over-year to -$0.2 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $6.0 million (up 1610.85% YoY) and the FY2025 annual result came in at $2.3 million, down 53.01% from the prior year.
- Non Operating Investment Income was -$0.2 for Q4 2024 at Pharming, up from -$21000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $5.1 million in Q2 2024 and bottomed at -$1.2 million in Q4 2022.
- A 5-year average of $510035.9 and a median of -$30000.0 in 2021 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2022 — Non Operating Investment Income sank 3900.0% — and 2023, when it soared 177.5%.
- Pharming's Non Operating Investment Income stood at -$71537.4 in 2020, then soared by 58.06% to -$30000.0 in 2021, then sank by 3900.0% to -$1.2 million in 2022, then surged by 177.5% to $930000.0 in 2023, then plunged by 100.0% to -$0.2 in 2024.
- Business Quant data shows PHAR's Non Operating Investment Income at -$0.2 in Q4 2024, -$21000.0 in Q3 2024, and $5.1 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Pharming | 8.69 Bn | 8.64 Bn | 65.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -0.20 |
| Dec 31, 2024 | -0.20 |
| Sep 30, 2024 | -21,000.00 |
| Sep 30, 2024 | -21,000.00 |
| Jun 30, 2024 | 5.14 Mn |
| Jun 30, 2024 | 5.14 Mn |
| Dec 31, 2023 | 930,000.00 |
| Dec 31, 2023 | 930,000.00 |
| Dec 31, 2022 | -1.20 Mn |
| Dec 31, 2022 | -1.20 Mn |
| Dec 31, 2021 | -30,000.00 |
| Dec 31, 2021 | -30,000.00 |
| Sep 30, 2021 | -100,239.42 |
| Sep 30, 2021 | -100,239.42 |
| Dec 31, 2020 | -71,537.39 |
| Dec 31, 2020 | -71,537.39 |
| Sep 30, 2020 | -54,899.63 |
| Sep 30, 2020 | -54,899.63 |
| Dec 31, 2019 | 231,339.52 |
| Dec 31, 2019 | 231,339.52 |